Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension
This product will be manufactured at Lupin's Nagpur facility in India
Selexipag tablet is indicated in adults for the treatment of pulmonary arterial hypertension to delay disease progression and reduce the risk of hospitalization for PAH
The drug will be manufactured at the group's formulation facility at SEZ, Ahmedabad
The tablets are indicated for the treatment of pulmonary arterial hypertension
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
The company has received five final approvals
Subscribe To Our Newsletter & Stay Updated
